EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper

Andreas Meisel, Adela Della Marina, Paolo Doksani, Tim Hagenacker, Christoph Kleinschnitz, Heidrun H. Krämer, Jan D. Lünemann, Sven G. Meuth, Tobias Ruck, Ulrike Schara‐Schmidt, Christiane Schneider‐Gold, Benedikt Schoser, Michael Schroeter, Charlotte Schubert, Jörn Peter Sieb, Fritz Zimprich, Jana Zschüntzsch, Sarah Hoffmann

European Journal of Neurology · 2026-09 · 33 (9)

DOI: 10.1111/ene.70747 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals more heterogeneous outcomes and raises questions about optimal patient selection, therapy sequencing and integration into clinical practice. In Germany and Austria, early access following regulatory approval has facilitated clinical experience over recent years. This expert opinion paper aims to combine current evidence with clinical experience to guide the use of C5‐I and FcRn‐I in everyday care. Methods A panel of 18 neurologists from Germany and Austria, including two paediatric neurologists, evaluated study data and real‐world experiences. Through structured discussion and a consensus process, they developed evidence‐ and experience‐based recommendations on integrating targeted immunotherapies into existing treatment algorithms. Results The panel provides practical recommendations for managing (highly) active gMG in adults, focusing on C5‐I (eculizumab, ravulizumab, zilucoplan) and FcRn‐I (efgartigimod, rozanolixizumab). The statements cover initiation criteria, sequencing and switching within and between drug classes and transitions to intensified immunomodulatory therapies (rituximab, apheresis, intravenous or subcutaneous immunoglobulin), as well as special considerations for juvenile MG. Conclusions This expert statement provides a practice‐oriented framework integrating current evidence and clinical experience to support individualised therapeutic decision‐making in gMG.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →